Privately-held biotech Alligator Bioscience has brought in fellow Swedish company BioInvent International (STO: BINV) to do the process development and manufacturing of its immuno-oncology drug candidate ADC-1015.
This will allow Alligator to start early clinical trials of this candidate, which is a bispecific immune-activating antibody that targets OX40 and CTLA-4.
Since both OX40 and CTLA-4 are expressed on T cells in the tumor area, ADC-1015 is expected to induce strong tumor-directed immune activation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze